ITCC-070 Daratumumab

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

ITCC-070 Daratumumab

An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age with Relapsed/Refractory Precursor B-cell or T cell Acute Lymphoblastic Leukemia

Promotor Name : Janssen

Investigator Name : 

Trial registered on : NCT03384654